First Name
Last Name
Stanford university
Email ID
San mateo
United States
Zip code
Area of Research
Biochemistry, molecular biology, epigenetics, cancer, tumor
Area of Expertise
Biochemistry, molecular biology, epigenetics, cancer, tumor
Brief Description of Research Interest:
My primary focus for both my PhD and postdoctoral studies have been chromatin biology and it’s impact on oncology. Briefly, in my PhD, I focused on the role of histone methyl transferase EZH2 in melanoma, where my work involved understanding complex EZH2-mediated epigenetic mechanisms in melanoma resulting in repression of tumor suppressor genes such as E-cadherin and RUNX3. Alongside, I also pursued another study unveiling the complex epigenetic-mediated regulation of c-Myc in Merkel Cell Carcinoma.

My post-doctoral work involves identifying the role of the epigenetic regulator NSD2 in oncogenesis independently and in conjunction with other oncogenic drivers such as Ras. Alongside, I am also investigating the contribution of NSD2 gain of function mutation in B cell development leading to lymphoid disorders.
Representative Publications:
 P Zanoni*, K Steindl*, D Sengupta*, et. al. (2021). “Loss-of-function and missense variants in NSD2 cause decreased methylation activity and are associated with a distinct developmental phenotype.” Genetics in Medicine, 1-10 (* Authors contributed equally), 
2. G Yuan, N Flores, S Hausmann, S Lofgren, V Kharchenko, M Ibanez, D Sengupta, X Lu, I Czaban, D Azhibek, S Vicent, W Fischle, M Jaremko, B Fang, I Wistuba, K Chua, J Roth, J Minna, N Shao, L Jaremko,  P Mazur & O Gozani (2021). “Elevated NSD3 histone methylation activity drives squamous cell lung cancer” Nature, 590 (7846), 504–508
3. W Li, W Tian, G Yuan, P Deng, D Sengupta, Z,Cheng, Y Cao, J Ren, Y Qin, Y Zhou, Y Jia, O Gozani, DJ  Patel, Z Wang (2021). Molecular basis of nucleosomal H3K36 methylation by NSD methyltransferases.  Nature, 590 (7846), 498-503.
4. B Shields, F Mahmoud, E Taylor, SD Byrum, D Sengupta, B Koss, G Baldini, S Ransom, K Cline, S  Mackintosh, R Edmondson, S Shalin, and AJ Tackett (2017). “Indicators of responsiveness to immune  checkpoint inhibitors.” Sci Rep, 7(1). 1-12.
5. D Sengupta, AJ Tackett (2016). “Proteomic Findings in Melanoma.” J Proteomics & Bioinform 9 (4).
6. D Sengupta, N Avaritt, S Shalin, A Tackett (2016). “Enhancer of zeste homolog 2 (EZH2) inhibition in  metastatic melanoma promotes tumor regression in vivo.” Cancer Research 76 (14 Supplement), 1146- 1146.
7. D Sengupta, S Byrum, N Avaritt, L Davis, L Orr, S Mackintosh, S Shalin, A Tackett (2016). “Quantitative  histone mass spectrometry identifies elevated histone H3 lysine 27 trimethylation in melanoma.” Molecular  and Cellular Proteomics, 15(3), 765-775.
8. D Sengupta, A Kannan, M Kern, M Moreno, E Vural, B Stack, J Suen, A Tackett and L Gao (2015).  â€œDisruption of BRD4 at H3K27Ac-enriched enhancer region correlates with decreased c-Myc expression  in Merkel cell carcinoma.” Epigenetics, 10(6), 460-466.
9. D Sengupta, N Avaritt, A Tackett (2015). “EZH2 Overexpression in Malignant Melanoma Represses E- cadherin and Promotes Invasion.” The FASEB Journal 29 (1 Supplement), 877.8.
10. U Udensi, A Tackett, S Byrum, N Avaritt , D Sengupta, et al. (2014). “Proteomics-Based Identification of  Differentially Abundant Proteins from Human Keratinocytes Exposed to Arsenic Trioxide.” J  Proteomics Bioinform 7 (7): 166-178.
11. N Avaritt, F Mahmoud, D Sengupta, I Makhoul, L Hutchins, A Tackett (2014). “Role of the EZH2 histone  ethyltransferase in melanoma.” Pigment Cell & Melanoma Research 27 (6).
12. N Avaritt, M Fade, M Reynolds, D Sengupta, I Makhoul, S Shalin, A Tackett (2013). “Cutaneous  Melanoma: Molecular Mechanisms and Current Therapeutic Approaches.” Melanoma: Molecular  Biology, Risk Factors and Treatment Options Chapter 6 pp.137-154. Hauppauge, New York: Nova  Science Publishers.